However, in individuals with type 2 diabetes, infusions of GIP(3-30)NH2 reduced glucagon concentrations (78), illustrating the potential of GIP receptor antagonism to limit the paradoxical postprandial hyperglucagonemia in individuals with type 2 diabetes (93). The gene discussed is GCG; the disease is type 2 diabetes mellitus.